BioSpace News Archive

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today reported that the oral myeloid kinome inhibitor HM43239 has demonstrated durable single agent activity in patients with relapsed or refractory acute myeloid leukemia (AML).

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced changes to its board of directors, including the appointment of Elaine M. Yang.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today announced data from an ongoing pivotal Phase 2 study (CIBI376A201) evaluating parsaclisib.

2seventy bio, Inc. (NASDAQ: TSVT) today announced data from its broad oncology cell therapy portfolio, including updated results from the CRB-402 study of bb21217 and new analyses from the pivotal KarMMa study of ABECMA® (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma, both in partnership with Bristol Myers Squibb (BMS).

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).

Akumin Inc. announced its financial results for the quarter ended September 30, 2021.

BeiGene and Nanjing Leads Biolabs, Inc. announced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), today provided a pipeline update on its programs, including the interim data presented from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma (R/R MM) at the 63rd American Society for Hematology (ASH) Annual Meeting and Exposition.

KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced its common stock has been added to the Nasdaq Biotechnology Index in accordance with an annual reconstitution of the index.

Bellicum Pharmaceuticals, Inc. announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550, which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock.